Novocure will present the final secondary endpoint results from the Phase 3 PANOVA-3 trial of its Tumor Treating Fields therapy for unresectable, locally advanced pancreatic cancer at the European Society for Medical Oncology (ESMO) GI Congress 2025.

Novocure will report financial results for the second quarter 2025 on July 24, 2025, before the U.S. financial markets open. Read more in our press release:

Results from the Phase 3 PANOVA-3 trial of Tumor Treating Fields (TTFields) therapy for #PancreaticCancer will be presented today at #ASCO25 and simultaneously published in theJournal of Clinical Oncology. Read our press release:

Today, Novocure announced two upcoming investor events. Read more in our press release:

Novocure today reported financial results for the first quarter ended March 31, 2025. Read the press release:

Novocure has received a CE Mark for its metastatic non-small cell lung cancer treatment, for use concurrently with immune checkpoint inhibitors or docetaxel, for adult patients who have progressed on or after a platinum-based regimen. See the press release

Novocure will report financial results for the first quarter 2025 on April 24, 2025, before the U.S. financial markets open, as well as host a conference call and webcast to discuss the financial results. Read the press release for more information:

Novocure announced today that management will participate in the Leerink Partners 2025 Global Healthcare Conference on Tuesday, March 11, 2025. For more information, read the press release:

Today, Novocure announced its financial results for the quarter and full year that ended December 31, 2024. For more information, read the press release:

Novocure has announced positive topline results from Phase 3 PANOVA-3 clinical trial of Tumor Treating Fields (TTFields) Therapy in unresectable locally advanced pancreatic cancer. Read the press release here:

Novocure reports Q3 financial results and announces the appointment of Christoph Brackmann as CFO, effective January 1, 2025. For more information, see our press releases:

FDA approves Novocure’s treatment for metastatic non-small cell lung cancer (mNSCLC) for use concurrently with PD-1/PD-L1 inhibitors or docetaxel in adult patients with mNSCLC who progressed on or after a platinum-based regimen:

Novocure will participate in the 2024 Wells Fargo Healthcare Conference on September 4. William Doyle, our Executive Chairman, will take part in a fireside chat at 4:30 p.m. EST, as well as one-on-one meetings with investors. Listen live on Sep 4 here:

This #WorldLungCancerDay, we thank the doctors, nurses, caregivers, patient organizations and all who support patients facing this difficult disease. #lungcancer

We reported financial results for the quarter ended June 30, 2024, including quarterly net revenues of $150 million, up 19% year-over-year, with 3,963 active patients on therapy as of June 30, up 11% compared to the same period in 2023. #earnings #NVCR

To learn more about Novocure’s efforts to support the brain tumor community, please visit

Today marks the 6th annual #GBMDay, when patients, caregivers, and advocates come together to support those living with #glioblastoma, remember those we have lost, and reaffirm our commitment to developing innovative treatments and, ultimately, a cure for this disease.

In honor of #GlioblastomaAwarenessDay (GBM Day), Mike Ambrogi, Novocure’s Senior Technology Fellow & Colin Gerner (@StacheStrong ), discussed how being present & advocating for those battling glioblastoma can impact their lives.

Glioblastoma (GBM) Awareness Day is coming up. On #GBMDay and every day, we recognize the impact of GBM, the most common primary brain cancer, on patients and caregivers. Read just a few of their stories:

We will report financial results for the second quarter 2024 on Thursday, July 25, 2024, before the U.S. financial markets open. Learn more: $NVCR